



PATIENT INFORMATION (Complete or Fax Existing Chart)	PRESCRIBER INFORMATION
Name: _____ DOB: _____ Address: _____ City, State, Zip: _____ Phone: _____ Alt. Phone: _____ Email: _____ SS#: _____ Gender: <input type="checkbox"/> M <input type="checkbox"/> F Weight: _____ (lbs) Ht: _____ Allergies: _____	Prescriber Name: _____ State License: _____ NPI #: _____ Tax ID: _____ Address: _____ City, State, Zip: _____ Phone: _____ Fax: _____ Office Contact: _____ Phone: _____

INSURANCE INFORMATION – AND – Send a copy of the patient's prescription/insurance cards (front & back)

Primary Insurance: _____ Plan #: _____ Group #: _____ RX Card (PBM): _____ BIN: _____ PCN: _____	Secondary Insurance (If Applicable): _____ Plan #: _____ Group #: _____ RX Card (PBM): _____ BIN: _____ PCN: _____
--	--

CLINICAL INFORMATION

ICD-10 Code (Required): _____ ICD-10 Description: _____
 Baseline Liver Enzymes, Including Bilirubin (Results): _____
 Date of Negative TB Test: _____ TB Test is Pending, Will Fax The Results

OMVOH™ ORDERS

Prescription type: New start Restart Continued therapy Total Doses Received: _____ Date of Last Injection/Infusion: _____

Crohn's Disease Diagnosis

Induction Dosing: <input type="checkbox"/> 3 x 300 mg/15 mL single dose vial	<input type="checkbox"/> 900 mg by intravenous infusion at Weeks 0,4, and 8	Quantity: _____
Maintenance Dosing: <input type="checkbox"/> 1 x 100 mg/mL Prefilled Pen AND 1 x 200 mg/mL Prefilled Pen given as two consecutive subcutaneous injections <input type="checkbox"/> 1 x 100 mg/mL Prefilled Syringe AND 1 x 200 mg/mL Prefilled Syringe given as two consecutive subcutaneous injections	<input type="checkbox"/> 300 mg given by subcutaneous injection, given as two consecutive injections of 100 mg and 200 mg in any order, at week 12 and every 4 weeks thereafter	Quantity: _____ Refills: _____

Ulcerative Colitis Diagnosis

Induction Dosing: <input type="checkbox"/> 300 mg / 15 mL single dose vial	<input type="checkbox"/> 300 mg by intravenous infusion at Weeks 0, 4, and 8	Quantity: _____
Maintenance Dosing: <input type="checkbox"/> 2 x Prefilled Pen 100 mg/mL given as two consecutive subcutaneous injections <input type="checkbox"/> 2 x Prefilled Syringe 100 mg/mL given as two consecutive subcutaneous injections	<input type="checkbox"/> 200 mg by subcutaneous injection, given as two consecutive injections of 100 mg each, at week 12 and every 4 weeks thereafter	Quantity: _____ Refills: _____

Pre-Medication	Dose/Strength	Directions
<input type="checkbox"/> Acetaminophen	<input type="checkbox"/> 500mg	<input type="checkbox"/> Take 1-2 tablets PO prior to infusion or post-infusion as directed
<input type="checkbox"/> Diphenhydramine	<input type="checkbox"/> 25mg IV/PO <input type="checkbox"/> 50mg IV/PO	<input type="checkbox"/> Take 1 tablet PO prior to infusion or as directed OR <input type="checkbox"/> Inject contents of 1 vial IV prior to infusion or as directed
<input type="checkbox"/> Methylprednisolone	<input type="checkbox"/> 40mg <input type="checkbox"/> 100mg	<input type="checkbox"/> Inject contents of 1 vial IV prior to infusion or as directed

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.



<input type="checkbox"/>	<input type="checkbox"/> 125mg	<input type="checkbox"/> Other: Inject 100mg IV 30 minutes prior to infusion
<input type="checkbox"/>		

INFUSION REACTION ORDERS

Mild reaction protocol:
 Diphenhydramine 25mg IV, one time, for pruritus.
If symptoms worsen, see orders for moderate to severe reactions.

Moderate reaction protocol:
 Acetaminophen 650mg PO, one time, for pyrexia or rigors
 Diphenhydramine 50mg IV, one time, for pruritus or urticaria
 Methylprednisolone 125mg IV, one time, for respiratory or neurologic symptoms
If symptoms worsen, see interventions for severe reactions

Severe reaction protocol: (Call 911 if initiated):
 Titrate oxygen via continuous flow per nasal cannula or face mask to maintain spO2 of greater than ninety-five percent (>95%)
 Diphenhydramine 50mg IV, one time, for respiratory symptoms, edema, or anaphylaxis
 Methylprednisolone 125mg IV, one time, for respiratory symptoms, edema, or anaphylaxis
 Sodium Chloride 0.9% 500mL IV over 30-60 min, one time, for cardiovascular symptoms
 Epinephrine 0.3mg/0.3mL IM into mid-antrolateral aspect of thigh of anaphylaxis, may repeat x1 in 5-15 minutes if symptoms are not resolved or worsen

FLUSHING & LOCKING ORDERS

Flushing Protocol (>66lbs/33kg)

PIV and Midline: <input checked="" type="checkbox"/> 0.9% Sodium Chloride 2-5mL IV flush before and after each infusion	Implanted Port, PICC, Tunneled Catheter, and Non-tunneled Catheter: <input checked="" type="checkbox"/> 0.9% Sodium Chloride 5mL IV flush before infusion/lab draw and 10mL IV flush after infusion/lab draw
---	--

Locking Protocol (>66lbs/33kg)

PIV and Midline: <input checked="" type="checkbox"/> Heparin Sodium 10 units/mL 1mL IV final flush post normal saline flush	PICC: <input checked="" type="checkbox"/> Heparin Sodium 10 units/mL 3mL IV final flush post normal saline flush	Implanted Port, Tunneled Catheter, and Non-tunneled Catheter: <input checked="" type="checkbox"/> Heparin Sodium 100 units/mL 3-5mL IV final flush post normal saline flush
---	--	---

**** May substitute Dextrose 5% in Water, or alternative, for 0.9% Sodium Chloride, when indicated due to incompatibility with medications being infused**

SIGNATURE

We hereby authorize Talis Healthcare LLC to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral.

X _____ Date: _____
 Prescriber Signature

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic, and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.